Vertex Pharmaceuticals Incorporated
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

Last updated:

Abstract:

The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

Status:
Grant
Type:

Utility

Filling date:

26 Dec 2018

Issue date:

20 Apr 2021